Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Melanoma
Interventions
DRUG

dacarbazine plus Genasense

Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.

DRUG

dacarbazine plus placebo

Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.

Trial Locations (77)

2050

Sydney Cancer Center, Royal Prince Alfred Hospital, Camperdown

18015

St. Luke's Cancer Center, Bethlehem

19107

Thomas Jefferson University Hospital, Philadelphia

36607

University of South Alabama Hospital, Mitchell Cancer Institute, Mobile

38120

The West Clinic, Memphis

51101

Siouxland Hematology Oncology Associates, Sioux City

59101

Hematology Oncology Centers of the Northern Rockies, Billings

73112

Cancer Care Associates, Oklahoma City

74104

Cancer Care Associates, Site 1, Tulsa

75246

Texas Oncology - Sammons Cancer Center, Dallas

92024

San Diego Pacific Oncology and Hematology Associates Inc., Encinitas

95403

Redwood Regional Medical Group, Inc., Santa Rosa

02115

Dana Farber Cancer Institute, Boston

07960

Morristown Memorial - Atlantic Healthcare System, Morristown

77030-4009

MD Anderson Cancer Center at University of Texas, Houston

Unknown

Calvary Mater Newcastle, Newcastle

Westmead Hospital, Westmead

Universitatsklinik fur Dermatologie und Venerologie, Medizinische Universitat Innsbruck, Innsbruck

Landesklinikum St. Polten, Sankt Pölten

Medical University of Vienna, Vienna General Hospital, Vienna

London Regional Cancer Program, London

Princess Margaret Hospital, Toronto

Charles University, Dermatology Department, Prague

CHU Saint Jacques, Besançon

Hopital Saint-Andre, Bordeaux

CHU Ambroise Pare, Boulogne-Billancourt

CHU Hotel Dieu, Clermont-Ferrand

CHU de Dijon, Hopital du Bocage Sud, Dijon

CHU de Grenoble, Hopital Albert Michallon, Grenoble

Centre Hospitalier du Mans, Le Mans

CHRU de Lille, Hopital Claude Huriez, Lille

Hopital de l'Hotel Dieu, Lyon

Hopital Sainte Marguerite, Marseille

Hopital Saint Eloi, Montpellier

CHU Hotel Dieu, Nantes

Hopital Saint-Louis, Paris

Hopital Robert Debre, Reims

CHU CH Nicolle, Rouen

Institut Gustave Roussy, Villejuif

Charite Universitatsmedizin Berlin, Berlin

Vivantes Klinikum im Friedrichshain, Berlin

Vivantes Klinikum Neukoln, Klinik fur Dermatologie und Venerologie, Berlin

Klinik fur Dermatologie und Allergologie der Ruhr-Universitat Bochum, Bochum

Klinik und Poliklinik fur Dermatologie und Venerologie, Cologne

Helios Klinikum Erfurt, Erfurt

Klinik fur Dermatologie, Allergologie und Venerologie, Universitatsklinikum Essen, Essen

Universitatsklinikum Freiburg, Freiburg im Breisgau

Hautklinik Linden, Hanover

Klinikum der Friedrich-Schiller-Universitat Jena, Jena

Universitatklinikum A. o. R., Leipzig

Hospital of the University of Schleswig-Holstein, Lübeck

Universitats-Hautklinik Mainz, Mainz

Universitatsklinikum Mannheim, Mannheim

Universitatsklinikum Giessen und Marburg GmbH, Klinik fur Dermatologie und Allergologie, Marburg

Klinik und Poliklinik fur Hautkrankheiten, Münster

Helios Vogtland-Klinikum Plauen, Plauen

Klinikum Quedlinburg, Quedlinburg

Dermatologische Klinik und Poliklinik, Regensburg

Hautklinik Universitat Tubingen, Tübingen

Ospedale San Salvatore, Coppitto-L'Aquila

Istituto Nazionale dei Tumori, Milan

"Istituto Nazionale dei Tumori G. Pascale", Napoli

IFO Instituto Regina-Elena - IRCCS, Rome

Istituto Dermopatico dell'Immacolata, Rome

Azienda Ospedaliera Universitaria di Siena, Siena

Szpital Akademii Medycznej w Gdansku, Gdansk

Wielkopolskie Centrum Onkologii, Poznan

Hospital Clinic I Provincial de Barcelona, Barcelona

Hospital Germans Trias I Pujol, Barcelona

Hospital Gregorio Maranon, Madrid

Clinica Universitaria de Navarra, Navarra

University Hospital Zurich, Zurich

Guy's Hospital, London

The Royal Marsden Hospital, London

Christie Hospital, Manchester

Nottingham University Hospitals NHS Trust, City Campus, Nottingham

Weston Park Hospital, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genta Incorporated

INDUSTRY

NCT00518895 - Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | Biotech Hunter | Biotech Hunter